GAL and neoplasm: These naturally occurring antibodies, especially the anti-Gal response, might also have other clinical consequences for immunotherapy [74] in the context of tolerance [75,76], cross-presentation of tumor antigens [77] and increased immunogenicity of cell-based and protein-based vaccines [66].